StockNews.com Begins Coverage on Syros Pharmaceuticals (NASDAQ:SYRS)

Research analysts at StockNews.com began coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research report issued on Friday. The firm set a “sell” rating on the stock.

A number of other equities analysts have also recently commented on SYRS. Piper Sandler reissued an “overweight” rating and issued a $5.00 price objective (down from $13.00) on shares of Syros Pharmaceuticals in a research note on Tuesday, August 13th. TD Cowen reissued a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. JMP Securities reaffirmed a “market perform” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. Brookline Capital Management reissued a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Finally, HC Wainwright restated a “neutral” rating and set a $1.00 price target (down previously from $6.00) on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $3.33.

Syros Pharmaceuticals Stock Performance

Shares of Syros Pharmaceuticals stock opened at $0.27 on Friday. The company’s fifty day moving average is $1.68 and its 200 day moving average is $3.40. The company has a quick ratio of 2.25, a current ratio of 2.25 and a debt-to-equity ratio of 1.97. The stock has a market cap of $7.28 million, a price-to-earnings ratio of -0.09 and a beta of 1.59. Syros Pharmaceuticals has a twelve month low of $0.18 and a twelve month high of $8.17.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its earnings results on Thursday, October 31st. The company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.08. During the same period in the prior year, the company posted ($1.35) earnings per share. Sell-side analysts forecast that Syros Pharmaceuticals will post -2.94 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Jason Haas bought 35,363 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The stock was bought at an average price of $1.55 per share, with a total value of $54,812.65. Following the completion of the transaction, the chief financial officer now directly owns 59,915 shares of the company’s stock, valued at approximately $92,868.25. The trade was a 144.03 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Nancy A. Simonian sold 134,713 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $0.27, for a total transaction of $36,372.51. Following the completion of the sale, the director now owns 41,070 shares of the company’s stock, valued at approximately $11,088.90. This trade represents a 76.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have acquired a total of 130,707 shares of company stock worth $206,491 in the last three months. Corporate insiders own 12.26% of the company’s stock.

Institutional Investors Weigh In On Syros Pharmaceuticals

A number of large investors have recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in shares of Syros Pharmaceuticals by 21.3% during the first quarter. Vanguard Group Inc. now owns 928,046 shares of the company’s stock valued at $4,965,000 after buying an additional 163,234 shares during the last quarter. Virtu Financial LLC purchased a new stake in Syros Pharmaceuticals during the 1st quarter valued at about $64,000. Acadian Asset Management LLC increased its holdings in shares of Syros Pharmaceuticals by 101.5% in the second quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock valued at $178,000 after purchasing an additional 17,416 shares during the period. Certuity LLC purchased a new position in shares of Syros Pharmaceuticals in the second quarter worth about $109,000. Finally, GSA Capital Partners LLP acquired a new stake in shares of Syros Pharmaceuticals during the third quarter worth about $34,000. Hedge funds and other institutional investors own 91.47% of the company’s stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.